Glucagon-like peptide 1 and appetite

Trends in Endocrinology and Metabolism

Volumn 24, Issue 2, 2013, Pages 85-91

  Dailey, Megan J ^a   Moran, Timothy H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Appetite; Food intake; Gastrointestinal motility; GLP 1

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; LIRAGLUTIDE;

ANOREXIA; APPETITE; BLOOD BRAIN BARRIER; FOOD INTAKE; GASTROINTESTINAL MOTILITY; GLUCOSE HOMEOSTASIS; HUMAN; IMMUNOREACTIVITY; INTESTINE INNERVATION; INTRACELLULAR SIGNALING; L CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SATIETY; STOMACH EMPTYING; TASTE AVERSION;

APPETITE; EATING; GASTROINTESTINAL MOTILITY; GLUCAGON-LIKE PEPTIDE 1; HUMANS;

EID: 84873134524     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2012.11.008     Document Type: Review

References (78)

1. Mojsov S., et al. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J. Biol. Chem. 1986, 261:11880-11889.
2. Orskov C., et al. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994, 43:535-539.
3. Edholm T., et al. Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis. Neurogastroenterol. Motil. 2010, 22:1191-1200.
4. McIntyre R.S., et al. The neuroprotective effects of GLP-1: Possible treatments for cognitive deficits in individuals with mood disorders. Behav. Brain Res. 2013, 237C:164-171.
5. Drucker D.J., Rosen C.F. Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology. Diabetologia 2011, 54:2741-2744.
6. Vahl T.P., et al. Meal-anticipatory glucagon-like peptide-1 secretion in rats. Endocrinology 2010, 151:569-575.
7. Dailey M.J., et al. Disassociation between preprandial gut peptide release and food-anticipatory activity. Endocrinology 2012, 153:132-142.
8. Rask E., et al. Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 2001, 24:1640-1645.
9. Roberge J.N., Brubaker P.L. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology 1993, 133:233-240.
10. Reimer R.A., et al. A human cellular model for studying the regulation of glucagon-like peptide-1 secretion. Endocrinology 2001, 142:4522-4528.
11. Rocca A.S., Brubaker P.L. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 1999, 140:1687-1694.
12. Larsen P.J., et al. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 1997, 77:257-270.
13. Grill H.J., et al. Attenuation of lipopolysaccharide anorexia by antagonism of caudal brain stem but not forebrain GLP-1-R. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004, 287:R1190-R1193.
14. Rinaman L. Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus. Am. J. Physiol. 1999, 277:R582-R590.
15. Rinaman L. A functional role for central glucagon-like peptide-1 receptors in lithium chloride-induced anorexia. Am. J. Physiol. 1999, 277:R1537-R1540.
16. Zhao S., et al. Hindbrain leptin and glucagon-like-peptide-1 receptor signaling interact to suppress food intake in an additive manner. Int. J. Obes. (Lond.) 2012, 36:1522-1528.
17. Rinaman L., Rothe E.E. GLP-1 receptor signaling contributes to anorexigenic effect of centrally administered oxytocin in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2002, 283:R99-R106.
18. Shimizu I., et al. Identification and localization of glucagon-like peptide-1 and its receptor in rat brain. Endocrinology 1987, 121:1076-1082.
19. Kanse S.M., et al. Identification and characterization of glucagon-like peptide-1 7-36 amide-binding sites in the rat brain and lung. FEBS Lett. 1988, 241:209-212.
20. Vahl T.P., et al. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 2007, 148:4965-4973.
21. Bullock B.P., et al. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996, 137:2968-2978.
22. Nakagawa A., et al. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton. Neurosci. 2004, 110:36-43.
23. Merchenthaler I., et al. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J. Comp. Neurol. 1999, 403:261-280.
24. D'Alessio D., et al. Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma: evidence for selective release of GLP-1 in the lymph system. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 293:R2163-R2169.
25. Hansen L., et al. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999, 140:5356-5363.
26. Kieffer T.J., et al. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995, 136:3585-3596.
27. Holst J.J., Deacon C.F. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 2005, 48:612-615.
28. Amato A., et al. Peripheral motor action of glucagon-like peptide-1 through enteric neuronal receptors. Neurogastroenterol. Motil. 2010, 22. 664-e203.
29. Turcot V., et al. DPP4 gene DNA methylation in the omentum is associated with its gene expression and plasma lipid profile in severe obesity. Obesity (Silver Spring) 2011, 19:388-395.
30. Miyazaki M., et al. Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism. Mol. Med. Report 2012, 5:729-733.
31. Moran G.W., et al. Dipeptidyl peptidase-4 expression is reduced in Crohn's disease. Regul. Pept. 2012, 177:40-45.
32. Orskov C., et al. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 1996, 45:832-835.
33. Kastin A.J., et al. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J. Mol. Neurosci. 2002, 18:7-14.
34. Schirra J., et al. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 2006, 55:243-251.
35. Hellstrom P.M., et al. GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterol. Motil. 2008, 20:649-659.
36. Yoder S.M., et al. Stimulation of incretin secretion by dietary lipid: is it dose dependent?. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 297:G299-G305.
37. Imeryuz N., et al. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am. J. Physiol. 1997, 273:G920-G927.
38. Wettergren A., et al. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am. J. Physiol. 1998, 275:G984-G992.
39. Daniel E.E., et al. Local, exendin-(9-39)-insensitive, site of action of GLP-1 in canine ileum. Am. J. Physiol. Gastrointest. Liver Physiol. 2002, 283:G595-G602.
40. Tolessa T., et al. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig. Dis. Sci. 1998, 43:2284-2290.
41. Wettergren A., et al. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 1997, 40:597-601.
42. Gulpinar M.A., et al. Glucagon-like peptide (GLP-1) is involved in the central modulation of fecal output in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 2000, 278:G924-G929.
43. Ayachi S.E., et al. Contraction induced by glicentin on smooth muscle cells from the human colon is abolished by exendin (9-39). Neurogastroenterol. Motil. 2005, 17:302-309.
44. Nakade Y., et al. Glucagon like peptide-1 accelerates colonic transit via central CRF and peripheral vagal pathways in conscious rats. Auton. Neurosci. 2007, 131:50-56.
45. Law N.M., et al. Cholinergic stimulation enhances colonic motor activity, transit, and sensation in humans. Am. J. Physiol. Gastrointest. Liver Physiol. 2001, 281:G1228-G1237.
46. Williams D.L., et al. Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. Diabetes 2006, 55:3387-3393.
47. McClean P.L., et al. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci. 2011, 31:6587-6594.
48. Chelikani P.K., et al. Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005, 288:R1695-R1706.
49. Larsen P.J., et al. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 2001, 50:2530-2539.
50. Turton M.D., et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996, 379:69-72.
51. Tang-Christensen M., et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am. J. Physiol. 1996, 271:R848-R856.
52. Kastin A.J., Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int. J. Obes. Relat. Metab. Disord. 2003, 27:313-318.
53. Williams D.L., et al. Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 2009, 150:1680-1687.
54. Abbott C.R., et al. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res. 2005, 1044:127-131.
55. Talsania T., et al. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 2005, 146:3748-3756.
56. Ruttimann E.B., et al. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 2009, 150:1174-1181.
57. Zhang J., Ritter R.C. Circulating GLP-1 and CCK-8 reduce food intake by capsaicin-insensitive, nonvagal mechanisms. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2012, 302:R264-273.
58. Baggio L.L., et al. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 2004, 127:546-558.
59. Strubbe J., van Dijk G W.P. Involvement of central GLP-1 circuitry in gastrointestinal motility. European Winter Conference on Brain Research 2001, Abstract 100.
60. Hayes M.R., et al. Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation. Endocrinology 2008, 149:4059-4068.
61. Hayes M.R., et al. Endogenous leptin signaling in the caudal nucleus tractus solitarius and area postrema is required for energy balance regulation. Cell Metab. 2010, 11:77-83.
62. Barrera J.G., et al. Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function. J. Neurosci. 2011, 31:3904-3913.
63. Sandoval D.A., et al. Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes 2008, 57:2046-2054.
64. Larsen P.J., et al. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 1997, 138:4445-4455.
65. Seo S., et al. Acute effects of glucagon-like peptide-1 on hypothalamic neuropeptide and AMP activated kinase expression in fasted rats. Endocr. J. 2008, 55:867-874.
66. Zhang, H. (2009) The Role of Glucagon-Like Peptide-1 on Food Intake, Glucokinase Expression and Fatty Acid Metabolism (ETD 07072009-212904), Louisiana State University.
67. Bugarith K., et al. Basomedial hypothalamic injections of neuropeptide Y conjugated to saporin selectively disrupt hypothalamic controls of food intake. Endocrinology 2005, 146:1179-1191.
68. Blevins J.E., Baskin D.G. Hypothalamic-brainstem circuits controlling eating. Forum Nutr. 2010, 63:133-140.
69. Kinzig K.P., et al. CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors. J. Neurosci. 2003, 23:6163-6170.
70. Sarkar S., et al. Glucagon like peptide-1 (7-36) amide (GLP-1) nerve terminals densely innervate corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Brain Res. 2003, 985:163-168.
71. Uehara A., et al. Anorexia induced by interleukin 1: involvement of corticotropin-releasing factor. Am. J. Physiol. 1989, 257:R613-R617.
72. Alhadeff A.L., et al. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology 2012, 153:647-658.
73. Dossat A.M., et al. Glucagon-like peptide 1 receptors in nucleus accumbens affect food intake. J. Neurosci. 2011, 31:14453-14457.
74. Thiele T.E., et al. Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats. Am. J. Physiol. 1997, 272:R726-R730.
75. Kinzig K.P., et al. The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J. Neurosci. 2002, 22:10470-10476.
76. McMahon L.R., Wellman P.J. Decreased intake of a liquid diet in nonfood-deprived rats following intra-PVN injections of GLP-1 (7-36) amide. Pharmacol. Biochem. Behav. 1997, 58:673-677.
77. Scott K.A., Moran T.H. The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 293:R983-R987.
78. Mann R.J., et al. The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4. Br. J. Pharmacol. 2010, 160:1973-1984.